Press Releases
GT Biopharma Provides Second Quarter 2021 Business Update
GT Biopharma to Host Conference Call to Discuss Second Quarter 2021 Results
GT Biopharma Announces Positive Preclinical Results For GTB-5550 B7H3 TriKE™
GT Biopharma Announces $16 million in Warrant Exercise Proceeds
GT Biopharma Announces Sponsored Research Agreement With Dr. Jeffrey S. Miller Of The University Of Minnesota
GT Biopharma CEO, Tony Cataldo to Present at Sir Anthony Ritossa's Global Family Office Investment Summit
GT Biopharma Announces Interim GTB-3550 Trike™ Monotherapy Clinical Trial Results At 2021 Raymond James Human Health Innovation Conference
Dr. Jeffrey S. Miller to Present on Progress of GTB-3550 TriKE™ Phase I Trial Accompanying GT Biopharma's Company Presentation at Raymond James Human Health Innovation Conference
GT Biopharma to Present at Raymond James Human Health Innovation Conference
